Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost; Minoxidil; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year

• Willingness to have micro-dot-tattoo applied to scalp

• Willingness to maintain same hair style, length and hair color during study

Exclusion Criteria:

• Drug or alcohol abuse within 12 months

• HIV positive

• Received hair transplants or had scalp reductions

• Use of hair weaves, hair extensions or wigs within 3 months

• Oral or topical minoxidil treatment within 6 months

• Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks